The DOI matches its Crossref record; 113 of the 114 references it cites were found in a registry or an index.
The emerging role of HDL in glucose metabolism
Abstract
A low plasma level of HDL cholesterol is an atherosclerotic risk factor; however, emerging evidence suggests that low HDL levels might also contribute to the pathophysiology of type 2 diabetes mellitus (T2DM) through direct effects on plasma glucose. In the past decade, animal and clinical studies have uncovered a previously undescribed spectrum of HDL actions, indicating that HDL may control glucose homeostasis through mechanisms including insulin secretion, direct glucose uptake by muscle via the AMP-activated protein kinase, and possibly enhanced insulin sensitivity. These effects are mediated by multiple cell types via mechanisms including preservation of cell function through cellular lipid removal and also via direct signaling events. We suggest a paradigm shift from HDL being a bystander to being an active player in diabetic pathophysiology, which raises the possibility that HDL elevation could be a novel therapeutic avenue for T2DM. The entry of HDL-raising agents of the cholesteryl ester transfer protein (CETP) inhibitor class into late-phase clinical trials creates potential for rapid clinical translation. This Review will discuss the emerging evidence for a role of HDL-mediated glucose regulation in the pathophysiology of T2DM, and will also outline the therapeutic potential for HDL elevation for the prevention and management of T2DM.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This finding is consistent with previous mechanistic evidence linking CETP inhibition and HDL-C elevation to improved glucose metabolism [33,34].”
From Efficacy and safety of obicetrapib in patients with dyslipidemia: An updated meta-analysis of randomized controlled trials (2025) · cites this paper as [34]
Citations
Cites
Inflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199
Ford, E. S., Giles, W. H., & Dietz, W. H. (2002) · JAMA · doi:10.1001/jama.287.3.356 · Cited by 6,698
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Inflammation, stress, and diabetes
Wellen, K. E., & Hotamisligil, G. S. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25102 · Cited by 4,143
A genome-wide association study identifies novel risk loci for type 2 diabetes
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007) · Nature · doi:10.1038/nature05616 · Cited by 2,993
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Monnier, L., Mas, E., Ginet, C., Michel, F., Villon, L., Cristol, J.-P., & Colette, C. (2006) · JAMA · doi:10.1001/jama.295.14.1681 · Cited by 2,444
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
Khera, A. V., Cuchel, M., de la Llera-Moya, M., Rodrigues, A., Burke, M. F., Jafri, K., French, B. C., Phillips, J. A., Mucksavage, M. L., Wilensky, R. L., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1001689 · Cited by 1,943
Flagged first, then by citations
1 of the 114 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 301–307 of 307
Artificial recombinant high-density protein nanocarriers for precision drug delivery
Li, W., Jia, N., Li, M., Jiang, Y., & Lu, J. (2026) · Chemical Science · doi:10.1039/d5sc09151a
Bo, J., Mo, H., Wu, F., Zhu, J., Yan, Q., Wang, F., & Cheng, M. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/8449810
Editorial: HDL and cardiovascular disease: mechanisms, clinical relevance, and therapeutic impacts
Wang, J., & Zhang, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1910207
Zhou, Y., & Zhu, J. (2026) · Medicine · doi:10.1097/md.0000000000050146
Bukasa, E. T., Musung, J. M., Mutombo, P. T., Mukuba, E. M., Kapya, H. K., Ngoie, S. M., Nsibu, L. N., Lubamba, B., Kakisingi, C. N., Mukuku, O. K., et al. (2026) · Advances in General Practice of Medicine · doi:10.25082/agpm.2026.01.003
Lin, D., Lin, G., & Liu, Z. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1887682
Nameni, F., Rezaei, S., & Maleki, Z. (2026) · Journal of Shahrekord University of Medical Sciences · doi:10.34172/jsums.1150
Metadata
- Authors
- Drew, B. G., Rye, K.-A., Duffy, S. J., Barter, P., & Kingwell, B. A.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- The Heart Research Institute (AU)
- The Alfred Hospital (AU)
- Corresponding author
- Kingwell, Bronwyn A.
- Venue
- Nature Reviews Endocrinology
- Published
- 2012-01-24
- Volume
- 8
- Issue
- 4
- Pages
- 237-245
- ISSN
- 1759-5029 (ISSN-L)
- 1759-5037
- OpenAlex
- W1982981124
- Cited by
- 307
- References
- 114
- Citations by year
- 2026: 14 · 2025: 33 · 2024: 36 · 2023: 29 · 2022: 24 · 2021: 23 · 2020: 16 · 2019: 18 · 2018: 14 · 2017: 22 · 2016: 19 · 2015: 15 · 2014: 21 · 2013: 16 · 2012: 6
- FWCI
- 2.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Reviews Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- State Government of Victoria
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- high-density lipoprotein, glucose metabolism, glucose homeostasis, type 2 diabetes, insulin secretion, AMPK, muscle glucose uptake, insulin sensitivity, CETP inhibitors, HDL-raising therapy, atherosclerosis, lipid removal
- MeSH terms
- Animals, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Insulin, Lipoproteins, HDL, Cholesterol, HDL
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
